Persistent Inflammatory Cells in Blood After Severe Asthma Treatment, New Study Finds
A groundbreaking study reveals that inflammatory immune cells remain in the blood of severe asthma patients even after biologic treatment, highlighting the need for further research into long-term effects and treatment strategies.
A recent study conducted by researchers at Karolinska Institutet in Sweden reveals that biologic therapies used for treating severe asthma may not completely eliminate inflammatory immune cells from the bloodstream. Despite significant improvements in patient symptoms, certain immune cells with high inflammatory potential persist or even increase during treatment with biologics like mepolizumab and dupilumab. These drugs, which target specific pathways involved in asthma inflammation, have transformed severe asthma management, but their long-term impacts on immune cell behavior are not fully understood.
The study analyzed blood samples from 40 patients before and during biologic therapy. Surprisingly, instead of diminishing, some key inflammatory immune cells actually showed elevated levels during treatment. This finding suggests that biologics might not address the root causes of airway inflammation entirely, raising questions about the potential for inflammation to recur once treatment is tapered or discontinued.
Utilizing advanced techniques like flow cytometry and single-cell sequencing, the research team identified these changes in immune cell profiles. The results could explain why airway inflammation often returns after stopping or reducing biologic therapy. Since biologics have been in use for less than a decade, the long-term effects on immune function remain largely unknown.
Further research aims to investigate long-term immune cell behavior and the effects on lung tissue, with ongoing studies focusing on patients with extended treatment histories. Understanding whether these immune cells contribute to persistent inflammation could be vital for developing more effective, lasting treatments for severe asthma.
This study emphasizes the importance of continued monitoring and research into the immunological impacts of biologic therapies, ensuring that treatment strategies evolve to achieve sustained remission in severe asthma patients.
Source: https://medicalxpress.com/news/2025-06-inflammatory-cells-blood-treatment-severe.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Estrogen's Role in Preventing Ferroptosis Offers New Insights Into Sex Differences in Kidney Disease Risk
New research reveals how estrogen inhibits ferroptosis, shedding light on why women are less susceptible to certain kidney injuries and opening new avenues for targeted therapies based on sex differences.
Florida Water Contamination: Decline in Vibrio Bacterial Cases Do Not Diminish Risks
Florida reports a decrease in Vibrio vulnificus cases in 2025, but the bacteria's danger remains. Learn about risks, symptoms, and prevention of this deadly waterborne infection.
Enhanced Prediction of Chronic Kidney Disease Progression Using Advanced AI Models
Researchers have developed advanced AI models that significantly improve prediction accuracy for CKD progression to ESRD, promoting earlier intervention and personalized patient care.
Hidden Impact of Childhood Neglect on White Matter Brain Structures
Child neglect can cause significant structural changes in the brain's white matter, impacting development and behavior. Recent research highlights the importance of early detection and targeted interventions to support affected children.